LT.Swing trade!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
(ClinicalTrials.gov processed this record on December 06, 2010)
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML) (VALOR)
This study is currently recruiting participants.
Last Updated: December 2, 2010 http://www.clinicaltrials.gov/ct2/show/NCT01191801?term=sunesis&rank=1
I am very happy for you,and all of us who hold a lot of shares! MY First buy @ $1.81 on Aug 9th 2009. http://messages.finance.yahoo.com/Business_%26_Finance/Investments/Stocks_%28A_to_Z%29/Stocks_A/threadview?bn=1315&tid=121878&mid=121886
That was his expectations! "We'll see if the market agrees with that assessment in the a.m. Unfortunately, it will probably be a snoozer."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=57398188
Ariad (ARIA) May Have Been Best at ASH Meeting
December 6, 2010 9:02 AM EST
TheStreet.com's Adam Feurstein noted that buyside sources, commenting on the American Society of Hematology annual meeting, stated that:
Ariad Pharmaceuticals Inc. (Nasdaq: ARIA) was the best story at the meeting. Seattle Genetics Inc. (Nasdaq: SGEN) was good but a small market, Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) data is tonight, Celgene Corporation (Nasdaq: CELG) comparable to Allos Therapeutics, Inc. (Nasdaq: ALTH).
http://www.streetinsider.com/FDA/Ariad+%28ARIA%29+May+Have+Been+Best+at+ASH+Meeting/6144734.html?si_email_click=2010120609
intune; I wish you the best. What a shame,some cannot see the forest,because the trees are in the way!!!
U.S. Stock Options With Biggest Changes in Implied Volatility
By Bloomberg News - Nov 29, 2010 9:30 AM MT http://www.bloomberg.com/news/2010-11-29/u-s-stock-options-with-biggest-changes-in-implied-volatility.html?cmpid=yhoo
Short term & daytrading. http://investorshub.advfn.com/boards/board.aspx?board_id=9413
$heff mention it early this morning,I shoulda jumped at pre mkt?? Oh well!! http://investorshub.advfn.com/boards/read_msg.aspx?message_id=57151345
No RS for awhile. "Sunesis Granted 180-Day Extension,until March 28, 2011" http://ih.advfn.com/p.php?pid=nmona&article=44575564&symbol=N%5ESNSS
Long time trader,Just get a little excited sometimes when the the market is crashing,and I'm in the GREEN!
Sorry,did not mean to touch any nerves!!!
Blasting off! Shorts are taking it in the shorts!!! Whoops,must have ticked someone off??(Spoke to soon).
"this pig " ??????
Reverse Split: Probably won't happen untill after 6/14/2011. This from Yahoo thread. <"please read my post on that issue (part 1 & part 2)
http://messages.finance.yahoo.com/Stocks...
As explained in the above. on Dec 14 2010 OXGN which is now traded on the Nasdaq Global Market will move to the Nasdaq Capital Market (since all conditions for initial listing to the Nasdaq Capital market are met - except for bid price) by doing so they will get extra 180 days to regain complaince
this was done lately by GNVC & SNSS
here are the lons with respect to GNVC & SNSS
SNSS:
http://finance.yahoo.com/news/Sunesis-re...
http://www.bizjournals.com/sanjose/stori...
http://finance.yahoo.com/news/Sunesis-Gr...
GNVC
http://finance.yahoo.com/news/GenVec-Ann...
http://finance.yahoo.com/news/GenVec-Ann...
Now here is the OXGN 8K delsiting document
http://biz.yahoo.com/e/100618/oxgn8-k.ht...
you will see in this document that
" if the Company has not regained compliance, it may be eligible for an additional grace period of 180 days if it meets the initial listing standards, with the exception of bid price, for The Nasdaq Capital Market"
So it it meest the "initial listing conditions for Nasdaq Capital market EXCEPT FOR BID PRICE" they can move to the Nasdaq CAPITAL MARKET and GET EXTRA 180 days
You can now ask - do they meet all initial listing conditions for Nasdaq Capital Market except for bid price - The answer is YES - to see that read my post on that
http://messages.finance.yahoo.com/Stocks...
Other documensts that you and other will probably want to read are:
a- The second one is the Nasdaq LIsting rules (will be refered as "Nasdaq listing rules" - this rules give the condition for continued listing and initial listing
http://www.nasdaq.com/about/nasdaq_listi...
b- The third document we need is the R/S proxy document (refred here as " proxy")
http://investor.oxigene.com/secfiling.cf...
The first one shows you the Nasdaq listing conditions for General Market/General Selected Market/Capital market
The 2nd one is the latest proxy
Also, as you will see in the proxy - OXGN asked to have the ability to "effect" R/S up unitill 6/14/2011 (looks familair) yes this is the date that they will need to REGAIN COMPLIANCE WITH BID PRICE on the NASDAQ CAPITAL MARKET this is why they have asked it just to make sure that if in 7 MONTHA FROM NOW they will not regain complaince then they will have this option
Hope this clarify the R/S issue "> http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_O/threadview?m=tm&bn=13686&tid=108096&mid=108096&tof=6&frt=2
Good read from Yahoo thread. < Ariad Pharma, After 18-plus Years, Sets Sights on Not One, But Two, Marketed Cancer Drugs
Ryan McBride 10/28/10
The cancer drug developer Ariad Pharmaceuticals (NASDAQ:ARIA) is headquartered on the same block in Cambridge, MA, as Millennium: The Takeda Oncology Company. Like Millennium has done with its game-changing cancer treatment bortezomib (Velcade), Ariad now has a big opportunity with the lead cancer drug in its pipeline, ridaforolimus.
Ariad, which has no marketed products, could get its first major product revenue from ridaforolimus, which is in a pivotal clinical trial for the treatment of soft tissue and bone sarcomas. Merck & Co. (NYSE:MRK), which took over development of the drug from Ariad through an amended licensing deal in May, is expected to report results of the Phase III trial sometime around the end of 2010. If the clinical trial is a success, the FDA could approve the drug next year.
It has taken Ariad, founded in 1991, the better part of two decades to get to this point. When I stopped by to visit on a sunny day last week, the firm’s chief scientist, Timothy Clackson, and two of his colleagues talked about cancer patients whose lives have already benefited from ridaforolimus or the second anti-cancer candidate in the firm’s pipeline, ponatinib. Clackson, who joined the company in December 1994, has waited a long time be talking about the potential of having one of the firm’s treatments on the market.
“I’ve been here for 16 years. As it turns out there are many leaders and scientists in our R&D group who have similar longevity and commitment to Ariad,” Clackson said, “and it means the world to be on the cusp of potentially bringing something to patients and the market.”
Ariad is on the cutting edge of developing what are known as targeted cancer therapies. Such drugs are designed to hit specific molecular targets to treat cancer, aiming to block the biological drivers of the disease while mostly sparing healthy tissues. The company decided to focus on targeted cancer drug development about a decade ago, Clackson says. Ariad is really just one of many companies pursuing this strategy: Novartis’s imatinib (Gleevec) and Roche’s bevacizumab (Avastin), two of the most successful new cancer treatments to reach the market over the past decade, are also targeted drugs.
What’s different here is that Ariad and Merck’s ridaforolimus would be the first targeted drug to be approved for treating sarcomas, which are malignancies of the bones and soft tissues.The Ariad/Merck drug has the potential to be a new treatment option for patients who have ended treatment with chemotherapy and who would take it rather than waiting to see whether their tumors stop progressing without their taking anti-cancer drugs.
Ariad doesn’t yet have the definitive proof it needs to win FDA approval, but it has been encouraged by what it has seen so far. Clackson recalled fondly his memory of meeting the first patient to be treated with the drug, a Texas woman whose sarcoma had been in remission for eight years, he said. The drug is also in development for breast tumors and other types of cancer.
Taking the long view, Ariad decided this spring to give up some of its ownership in ridaforolimus to Merck (amending its July 2007 partnership deal) in exchange for a $50 million upfront payment from Merck. Merck also paid Ariad $19 million to reimburse the firm for certain R&D costs related to the drug, took over all expenses of its development for sarcoma and other tumor types, and agreed to give Ariad double-digit royalties on potential sales of the drug and as much as $514 million in milestone payments. Importantly, the deal gave Ariad cash and resources to focus on the No. 2 drug in its pipeline, ponatinib, which has the potential to treat both blood cancers and solid tumors.
Last month, Ariad began a Phase II clinical trial to test ponatinib as a treatment for certain patients with chronic myeloid leukemia (CML) as well as those with lymphoblastic leukemia that overexpresses what’s known as the Philadelphia chromosome. The drug is another targeted cancer therapy and one for patients with a mutation makes their cancer immune to imatinib (Gleevec) and other treatments. The company hopes to seek approval of the drug based on the results of the current Phase II. Companies ordinarily need to complete three phases of study to win FDA approval, but in this case the agency has said a well-controlled mid-stage study might be sufficient if it shows compelling results for this rare condition.
There are 320 patients who are expected to enroll in the global single-arm, Phase II study of ponatinib. For patients with chronic disease, the study’s primary endpoint will be to measure the drug’s impact on cytogenetic response rates identified in patients’ tissue samples. And for patients with accelerated or blast forms of disease, the study will measure how much signs of the cancer are reduced in the patients’ blood samples as a primary endpoint, according to Ariad. The trial will also test whether patients have the specific gene mutation that makes their cancer resistant to existing drugs.
“We knew that we had something quite special with ponatinib, in terms of its expedited path to approval, so we wanted to be able to focus on it as much as we could,” Clackson said.
Ponatinib is following a similar development path as the current treatments for CML patients whose cancer is resistant to Gleevec, including Bristol-Myers Squibb’s dasatinib (Sprycel) and Novartis’s nilotinib (Tasigna). Ariad was able to show in the Phase I the safety of its drug and the effective dosage of it. If approved, ponatinib would be used for CML patients who have not responded to dasatinib or nilotinib. There are estimated 4,9000 new cases of CML in the U.S. per year, and most of them respond to Gleevec or the second-line therapies, so this would only be a serious option for a small number of people. Still, Ariad estimates that its initial annual revenue for the drug in this population would be about $450 million per year.
In a September 13 note to investors, the New York-based investment firm Oppenheimer was bullish about the prospects of Ariad’s latest ponatinib trial. “We see a high probability of positive (ponatinib) data in 2012, leading to a late-2012 [or] early-2013 approval,” the firm’s analysts wrote. The firm rated Ariad’s stock at “outperform.”
So it’s not out of the question that Ariad could go from having none to two products on the market in less than three years. If that becomes the case, Ariad can join Millennium in Cambridge’s small and distinguished club of biotech companies with revenue from product sales.
Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.
http://www.xconomy.com/boston/2010/10/28/ariad-pharma-after-18-plus-years-sets-sights-on-not-one-but-two-marketed-cancer-drugs/2/
Bledsoe Battle;<"Dr. Cortes was quite pleased with my initial response to the Ariad drug. The very fast improvement in my blast count was the main reason for excitement along with very few side effects on the medication. My initial response with my blast count went from 79% on day 1 to 1% on day 22...it has now bounced back to 8% over my last 3 blood draws and actually today it went back down a little to 6%."> Lots of prayers from All! http://bledsoebattle.blogspot.com/
This is great news,for REAL LONGS. NO partnering for Ponatinib!!!!!
Tuesday, October 19, 2010
Ty-Fighters Day 22; "Day 1 when I started the ponatnib, my blast % was at 79%.....meaning that 79% of the cells they looked at in my blood sample showed disease. Every blood draw since day 1 has shown the blast % to decrease, with my most recent blood draw showing that percentage down to 10. That was on day 20."
(Hopes and prayers for Tyler Bledsoe,and and many other CML patients)! http://bledsoebattle.blogspot.com/
WOW!!!!!!!!!!!!
Thursday, September 30, 2010
Ty-Fighters vs. Stormtroopers
Yesterday was a very good day for us! We were finally accepted into the Phase II trial in Houston. They were able to accept my liver function test from Seattle, and so we're off and running with a new drug to fight against my cancer. At the Bush International airport I took my first dose yesterday as we continued our whirlwind adventure from Seattle to Houston, and then home a day early re-directed from Houston to Chicago and finally home late last night around midnight. Mandy is a rock-star!! I cant imagine having a better caregiver. Not to take anything away from all my other caregivers which are all fantastic and always willing to be there for me, but she is so positive and so giving of herself. I always feel like we can accomplish anything when we are together!
http://bledsoebattle.blogspot.com/
It appears INCY Mkt cap,about a year and a half ago was about 250 million. We can hope for 2 billion Mkt for ARIA in the next year,or so.(PPS $12-$25). I love Dreaming!!!
<"this stock isn't performing similar to, say, INCY.">!!
YTD charts very close! http://finance.yahoo.com/echarts?s=INCY+Interactive#chart10:symbol=incy;range=ytd;compare=aria;indicator=volume;charttype=line;crosshair=on;ohlcvalues=0;logscale=on;source=undefined
Tuesday, September 28, 2010
If at first you don't succeed, try, try again
We got the news today that the crew at MD Anderson got permission to take Tyler's blood result from Monday, so (we think) he starts on the Ponatinib TOMORROW! We are so excited about this news and hope that his disease responds to this drug for the long term. Thanks for the many prayers being said on his behalf (and to LeAnn for changing the prayer from ALT going up to going down)!
I guess everything won't be settled in my mind until he actually takes the first dose, but this is a definite answer for us!
http://bledsoebattle.blogspot.com/2010/09/if-at-first-you-dont-succeed-try-try.html
Thursday, September 23, 2010:(Bledsoe Battle) << "We hope that TODAY is the day for Tyler to begin on Ponatinib (the new name for the Ariad drug)!">> Our hope here on this MB is of monetary values. We have to say prayers for the Bledsoe family,and others going into these trials!(I just lost my sister 6/9/10,to cancer).Paulie. http://bledsoebattle.blogspot.com/
Barron's 400 is a collection of 400 stocks of all sizes. They are ranked based on number of criteria. Here is the latest ranking and ARIA is ranked #4
As of Sept. 20, 2010
Highest grades in the Barron's 400
Ticker Grade Name
DECK 90.45 DECKERS OUTDOOR CORP.
IPXL 88.56 IMPAX LABORATORIES INC.
MSFT 88.33 MICROSOFT CORP.
ARIA 86.81 ARIAD PHARMACEUTICALS INC.
SYNT 86.45 SYNTEL INC.
As of September 20, 2010
Yes,and at least most of the day it stayed green!! http://finance.yahoo.com/echarts?s=OXGN#chart1:symbol=oxgn;range=1d;indicator=volume;charttype=line;crosshair=on;ohlcvalues=0;logscale=on;source=undefined
A good read for BIO TECH investors! "Changes Brewing at the FDA for Orphan Drugs- Expected Changes
While some advocates asked for comprehensive formal guidance from FDA on orphan drug development, the National Organization for Rare Diseases requested an explicit written statement from FDA reaffirming its commitment to flexibly applying current drug development standards for orphan drug development. Clinical knowledge of these orphan diseases is constantly evolving, and the agency may approach drug development differently as more is revealed about the diseases.
The Institute of Medicine will produce a report tentatively titled “Accelerating Rare Disease Research and Orphan Product Development.” The report will include discussions and recommendations on discovery, drug development, FDA, the clinical trial process, insurance, Medicare/Medicaid, and devices. This is expected to put additional pressure on FDA to revise and revamp the orphan drug development process.
We think that FDA will make explicit statements in its new 2011 guidance re-affirming its right to flexibility and discretion in enforcing those drug development guidelines already in place. We also think the 2011 guideline may particularly focus on the acceptance and validation of disease-appropriate surrogate endpoints, biostatistical powering of clinical trials, and the validity of historical disease progression or disease registry data as comparators.
http://www.genengnews.com/analysis-and-insight/changes-brewing-at-the-fda-for-orphan-drugs/77899338/
Sunday, September 5, 2010 Tyler is once again sprouting hair! It's just in time for the weather to start turning colder, so I am happy that he will have the little extra bit of insulation. It seems strange that he has had facial hair throughout, but the chemo does make him lose the hair on top of his head...
In any case, I hadn't posted a picture in a long time so I thought I would share his handsome face with friends and family again. :)
We are still enjoying the good news from last week and hope that his blood test results will continue to stay positive. If he can just coast long enough for the Ariad trial to open up (and convince them to take him on), then we have a shot at a new drug.
As Ariad has shown successful results for many patients who have disease that was resistant to the other drugs or just never reached a long term remission. The press release referenced above says:
"A complete hematologic response (CHR) was observed in 85 percent (22 of 26) of chronic phase CML patients evaluable for hematologic response (16 patients entered the study with a baseline CHR). A major hematologic response was observed in five of twelve (42 percent) evaluable patients with accelerated phase, blast phase or Ph+ ALL. " http://bledsoebattle.blogspot.com/
Anybody watching that last few seconds? That was pure manipulation,I saw 270k sell order @ $3.50, it was just a flash in the last few seconds!!!
History of NCT00781846
Brief title: Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)
Record State: RELEASED
Updated View Type of info changed
2008_10_28 Study Nothing (earliest version on record)
2008_11_05 Study Changes Recruitment, Location/Contact, Administrative, Misc.
2009_01_25 Study Changes Recruitment, Location/Contact, Misc.
2009_04_29 Study Changes Recruitment, Misc.
2009_06_02 Study Changes Protocol, Recruitment, Misc.
2009_07_20 Study Changes Recruitment, Misc.
2009_08_27 Study Changes Recruitment status, Recruitment, Misc.
2009_11_15 Study Changes Protocol, Recruitment, Location/Contact, Misc.
2010_06_02 Study Changes Recruitment, Administrative, Misc.
2010_08_26 Study Changes Protocol, Recruitment status, Recruitment, Location/Contact, Misc.
http://clinicaltrials.gov/archive/NCT00781846
You guys are scaring the shorts,keep it up!!!
I wonder if this is the same Hans?? http://ftbwtw.spaces.live.com/blog/cns/
Ridaforolimus trials Exspanding,very encouraging for long term investors!! http://clinicaltrialsfeeds.org/clinical-trials/results/term=Drug:+ridaforolimus?recr=Open Clinical Trials for ridaforolimus, 24 Total!! http://clinicaltrialsfeeds.org/clinical-trials/results/term=ridaforolimus
After hours! After Hours Volume: 355,193
17:22 $ 3.35 15,855 17:22 $ 3.35 15,855 17:18 $ 3.3485 2,178 17:16 $ 3.3515 1,311 17:09 $ 3.3491 200 17:00 $ 3.3481 17,979 16:56 $ 3.3519 15,855 16:50 $ 3.347 5,583 16:49 $ 3.347 93,896 16:48 $ 3.348 43,212 16:48 $ 3.35 1,141 16:47 $ 3.3502 5,296 16:46 $ 3.3483 348 16:45 $ 3.3483 5,200 16:42 $ 3.3506 1,143 16:38 $ 3.33 1,000 16:38 $ 3.3511 705 16:35 $ 3.3482 266 16:35 $ 3.3511 12,025 16:34 $ 3.3482 4,300 16:34 $ 3.3489 12,025 16:33 $ 3.3834 9,021 16:29 $ 3.3503 1,135 16:29 $ 3.35 48,958 16:29 $ 3.35 48,958 16:27 $ 3.35 8,999 16:25 $ 3.35 450 16:22 $ 3.35 300 16:17 $ 3.3506 5,700
Read more: http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx?selected=ARIA&mkttype=after&symbol=RIMM&symbol=ARIA#ixzz0ru0gCrKL
Form 8-K for ARIAD PHARMACEUTICALS INC
--------------------------------------------------------------------------------
25-Jun-2010
ARIAD also announced three other promotions or new positions: Frank G. Haluska, M.D., Ph.D. has been named Vice President, Clinical Research and Development and Chief Medical Officer; Edward M. Fitzgerald has been promoted to Executive Vice President and Chief Financial Officer; and Pierre F. Dodion, M.D., M.B.A. will move into the newly created position of Senior Vice President, Corporate Development.
No other material changes were made to the terms of the officers' employment. A copy of the press release announcing the promotions and new positions is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
ITEM 5.07 Submission of Matters to a Vote of Security Holders.
On June 24, 2010, the Company held its 2010 Annual Meeting of Stockholders. Of 109,459,191 shares of common stock issued and outstanding and eligible to vote as of the record date of April 28, 2010, a quorum of 93,677,867 shares, or approximately 85.6 % of the eligible shares, was present in person or represented by proxy. The following actions were taken at such meeting:
1. Reelection of the following Class 1 Directors to serve until the 2013 annual meeting and until their successors are duly elected and qualified.
Voted For Withheld Authority Broker Non-Vote
Athanase Lavidas, Ph.D. 47,639,967 539,789 45,498,111
Massimo Radaelli, Ph.D. 46,557,931 1,621,825 45,498,111
After the meeting, Jay R. LaMarche, A. Collier Smyth, M.D. and Robert M. Whelan, Jr. continued to serve as Class 2 Directors for terms that expire at the 2011 annual meeting and until their successors are duly elected and qualified, and Harvey J. Berger, M.D. and Wayne Wilson continued to serve as Class 3 Directors for terms that expire at the 2012 annual meeting and until their successors are duly elected and qualified.
2. Ratification of the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for 2010.
The voting results were 91,618,063 votes for, 1,724,990 votes against, 334,814 votes abstaining and no broker non-votes.
http://biz.yahoo.com/e/100625/aria8-k.html Lots of After hours activity!!
http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx?selected=ARIA&mkttype=after&symbol=RIMM&symbol=ARIA
For such a VERY LARGE holder,do you do your own DD?? You seem to be just very negative! Your beginning to look very phony!!!